Filing Details
- Accession Number:
- 0001140361-16-054573
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-02-23 16:41:51
- Reporting Period:
- 2016-02-22
- Filing Date:
- 2016-02-23
- Accepted Time:
- 2016-02-23 16:41:51
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1048477 | Biomarin Pharmaceutical Inc | BMRN | Pharmaceutical Preparations (2834) | 680397820 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1240122 | G Michael Grey | C/O Biomarin Pharmaceutical Inc. 105 Digital Drive Novato CA 94949 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2016-02-22 | 7,500 | $38.59 | 33,750 | No | 4 | M | Direct | |
Common Stock | Disposition | 2016-02-22 | 7,500 | $80.00 | 26,250 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) Common Stock | Disposition | 2016-02-22 | 7,500 | $0.00 | 7,500 | $38.59 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2008-11-22 | 2018-05-21 | No | 4 | M | Direct |
Footnotes
- Trade made pursuant to a 10b5-1 plan executed on August 14, 2015.
- All shares were sold at exactly $80.00.
- Original option grant vests 6/48ths on November 22, 2008, and 1/48th on the 22nd day of every month thereafter.
- Reflects the number of stock options that remain from this specific stock option grant following the reported transaction.